Products for Research Use Only

Brentuximab vedotin (solution)

CAT: 0804-HY-P99107A-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99107A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab , and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].
CAS Number
914088-09-8
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brentuximab-vedotin-solution.html
Purity
99.73
Solubility
10 mM in DMSO
Smiles
[Brentuximabvedotin(solution)]
Molecular Weight
153000 (average)
References & Citations
[1]Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15 (1) :9-19.|[2]Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102 (4) :1458-65.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported